

**Supplemental Table 1: Demographics and Family Representation in Pathogenic Variant Groupings**

<b>Dataset A:</b>	# of Pathogenic Variant Carriers/Families	# Variants	Variants Represented in Domain-Based Grouping	Baseline EYO (mean years/SD)	Baseline Age (mean years/SD)	Familial Age of Onset (mean years/SD)
<i>APP Transmembrane Domain</i>	25 / 17	6	APP:p.Val715Ala, APP:p.Ile716Phe, APP:p.Ile716Val, APP:p.Val717Ile, APP:p.Val717Leu, APP:p.Leu723Arg	-10.52/11.69	37.72/10.95	48.24/7.68
<i>PSEN2 Transmembrane Domain 2</i>	16 / 2	1	PSEN2:p.Asn141Ile	-11.53/10.09	38.62/9.93	50.16/NA
<i>PSEN1 Cytoplasmic Domain 4</i>	23 / 9	6	PSEN1:p.Ala275Val, PSEN1:p.Glu280Ala, PSEN1:p.Glu280Gly, PSEN1:p.Phe283Leu, PSEN1:p.Tyr288His, PSEN1:exon9del	-6.67/9.05	34.35/8.11	41.02/4.36
<i>PSEN1 Transmembrane Domain 2</i>	18 / 13	8	PSEN1:p.Asn135Ser, PSEN1:p.Asn135Tyr, PSEN1:p.Ile143Thr, PSEN1:p.Met139Ile, PSEN1:p.Met146Ile, PSEN1:p.Met146Leu, PSEN1:p.Met146Val, PSEN1:p.Thr147Ile	-5.50/7.20	32.11/6.27	37.61/6.28
<i>PSEN1 Transmembrane Domain 3</i>	13 / 7	6	PSEN1:p.Ser169Leu, PSEN1:p.Ser170Phe, PSEN1:p.Leu171Pro, PSEN1:p.Phe176Val, PSEN1:p.Ser178Pro, PSEN1:p.Glu184Asp	-6.10/6.13	35.46/8.17	41.56/6.81
<i>PSEN1 Transmembrane Domain 4</i>	21 / 14	5	PSEN1:p.Ile202Phe, PSEN1:p.Gly206Ala, PSEN1:p.Gly209Glu, PSEN1:p.Gly209Val, PSEN1:p.Ser212Tyr	-6.86/13.12	43.90/10.86	50.77/8.00
<i>PSEN1 Transmembrane Domain 5</i>	12 / 10	8	PSEN1:p.Gln222His, PSEN1:p.Ile229Phe, PSEN1:p.Leu226Arg, PSEN1:p.Ser230Asn, PSEN1:p.Met233Leu, PSEN1:p.Met233Thr, PSEN1:p.Leu235Val, PSEN1:p.Ile238Met	-8.25/8.89	38.50/9.48	46.75/9.79
<i>PSEN1 Transmembrane Domain 6</i>	28 / 12	7	PSEN1:p.Ala260Gly, PSEN1:p.Ala260Val, PSEN1:p.Val261Phe, PSEN1:p.Pro264Leu, PSEN1:p.Pro267Leu, PSEN1:p.Arg269His, PSEN1:p.Leu271Val	-8.44/11.62	43.57/11.39	52.01/6.24
<i>PSEN1 Transmembrane Domain 8</i>	16 / 4	2	PSEN1:p.Cys410Tyr, PSEN1:p.Ala426Pro	-7.24/13.26	37.00/11.71	44.24/5.56
<i>Ungrouped Carriers</i>	34 / 24	12	APP:p.Lys670_Met671delinsAsnLeu, APP:duplication, PSEN1:p.Ala79Val, PSEN1:p.Met84Val, PSEN1:p.Cys92Ser, PSEN1:p.Phe105Leu, PSEN1:p.Tyr115His, PSEN1:p.His163Arg, PSEN1:p.Gly217Arg, PSEN1:p.Leu219Pro, PSEN1:p.Thr245Pro, PSEN1:p.Ala431Glu	-9.74/10.74	37.18/10.61	46.92/7.53
<b>Dataset B:</b>						
<i>PSEN1 pathogenic variant prior to codon 200</i>	54 / 35	20	<i>PSEN1 variants in blue (above)</i>	-8.04/9.10	34.93/8.88	42.97/8.31
<i>PSEN1 pathogenic variant after codon 200</i>	107 / 55	33	<i>PSEN1 variants in red (above)</i>	-7.30/11.10	39.66/10.91	46.96/7.92

**Supplemental Table 2: Variant Coding DNA Reference Sequences**

Gene	Variant gDNA consequence	Variant cDNA consequence	Variant protein consequence
<i>APP</i>	chr21:g.27269938_27269939delinsGA	c.2010_2011delinsTC	p.Lys670_Met671delinsAsnLeu
<i>APP</i>	chr21:g.27264101A>G	c.2144T>C	p.Val715Ala
<i>APP</i>	chr21:g.27264099T>C	c.2146A>G	p.Ile716Val
<i>APP</i>	chr21:g.27264099T>A	c.2146A>T	p.Ile716Phe
<i>APP</i>	chr21:g.27264096C>T	c.2149G>A	p.Val717Ile
<i>APP</i>	chr21:g.27264096C>G	c.2149G>C	p.Val717Leu
<i>APP</i>	chr21:g.27264077A>C	c.2168T>G	p.Leu723Arg
<i>APP</i>	-	-	dup
<i>PSEN1</i>	chr14:g.73683933G>A	c.1229G>A	p.Cys410Tyr
<i>PSEN1</i>	chr14:g.73685869G>C	c.1276G>C	p.Ala426Pro
<i>PSEN1</i>	chr14:g.73685885C>A	c.1292C>A	p.Ala431Glu
<i>PSEN1</i>	chr14:g.73637653C>T	c.236C>T	p.Ala79Val
<i>PSEN1</i>	chr14:g.73637667A>G	c.250A>G	p.Met84Val
<i>PSEN1</i>	chr14:g.73637691T>A	c.274T>A	p.Cys92Ser
<i>PSEN1</i>	chr14:g.73637730T>C	c.313T>C	p.Phe105Leu
<i>PSEN1</i>	chr14:g.73640278T>C	c.343T>C	p.Tyr115His
<i>PSEN1</i>	chr14:g.73640338A>T	c.403A>T	p.Asn135Tyr
<i>PSEN1</i>	chr14:g.73640339A>G	c.404A>G	p.Asn135Ser
<i>PSEN1</i>	chr14:g.73640352G>C	c.417G>C	p.Met139Ile
<i>PSEN1</i>	chr14:g.73640363T>C	c.428T>C	p.Ile143Thr
<i>PSEN1</i>	chr14:g.73640371A>C	c.436A>C	p.Met146Leu
<i>PSEN1</i>	chr14:g.73640371A>G	c.436A>G	p.Met146Val
<i>PSEN1</i>	chr14:g.73640373G>C	c.438G>C	p.Met146Ile
<i>PSEN1</i>	chr14:g.73640375C>T	c.440C>T	p.Thr147Ile
<i>PSEN1</i>	chr14:g.73653568A>G	c.488A>G	p.His163Arg
<i>PSEN1</i>	chr14:g.73653586C>T	c.506C>T	p.Ser169Leu
<i>PSEN1</i>	chr14:g.73653589C>T	c.509C>T	p.Ser170Phe
<i>PSEN1</i>	chr14:g.73653592T>C	c.512T>C	p.Leu171Pro
<i>PSEN1</i>	chr14:g.73653606T>G	c.526T>G	p.Phe176Val
<i>PSEN1</i>	chr14:g.73653612T>C	c.532T>C	p.Ser178Pro
<i>PSEN1</i>	chr14:g.73659355A>C	c.552A>C	p.Glu184Asp
<i>PSEN1</i>	chr14:g.73659407A>T	c.604A>T	p.Ile202Phe
<i>PSEN1</i>	chr14:g.73659420G>C	c.617G>C	p.Gly206Ala
<i>PSEN1</i>	chr14:g.73659429G>A	c.626G>A	p.Gly209Glu
<i>PSEN1</i>	chr14:g.73659429G>T	c.626G>T	p.Gly209Val
<i>PSEN1</i>	chr14:g.73659438C>A	c.635C>A	p.Ser212Tyr
<i>PSEN1</i>	chr14:g.73659452G>C	c.649G>C	p.Gly217Arg
<i>PSEN1</i>	chr14:g.73659459T>C	c.656T>C	p.Leu219Pro
<i>PSEN1</i>	chr14:g.73659469G>T	c.666G>T	p.Gln222His
<i>PSEN1</i>	chr14:g.73659480T>G	c.677T>G	p.Leu226Arg
<i>PSEN1</i>	chr14:g.73659488A>T	c.685A>T	p.Ile229Phe
<i>PSEN1</i>	chr14:g.73659492G>A	c.689G>A	p.Ser230Asn
<i>PSEN1</i>	chr14:g.73659500A>C	c.697A>C	p.Met233Leu
<i>PSEN1</i>	chr14:g.73659501T>C	c.698T>C	p.Met233Thr
<i>PSEN1</i>	chr14:g.73659506C>G	c.703C>G	p.Leu235Val
<i>PSEN1</i>	chr14:g.73659517C>G	c.714C>G	p.Ile238Met
<i>PSEN1</i>	chr14:g.73659536A>C	c.733A>C	p.Thr245Pro
<i>PSEN1</i>	chr14:g.73664748C>G	c.779C>G	p.Ala260Gly
<i>PSEN1</i>	chr14:g.73664748C>T	c.779C>T	p.Ala260Val
<i>PSEN1</i>	chr14:g.73664750G>T	c.781G>T	p.Val261Phe
<i>PSEN1</i>	chr14:g.73664760C>T	c.791C>T	p.Pro264Leu
<i>PSEN1</i>	chr14:g.73664769C>T	c.800C>T	p.Pro267Leu
<i>PSEN1</i>	chr14:g.73664775G>A	c.806G>A	p.Arg269His
<i>PSEN1</i>	chr14:g.73664780C>G	c.811C>G	p.Leu271Val
<i>PSEN1</i>	chr14:g.73664793C>T	c.824C>T	p.Ala275Val
<i>PSEN1</i>	chr14:g.73664808A>C	c.839A>C	p.Glu280Ala
<i>PSEN1</i>	chr14:g.73664808A>G	c.839A>G	p.Glu280Gly
<i>PSEN1</i>	chr14:g.73664816T>C	c.847T>C	p.Phe283Leu
<i>PSEN1</i>	chr14:g.73664831T>C	c.862T>C	p.Tyr288His
<i>PSEN1</i>	chr14:g.73671096_73676953del15858	c.869-1998_956-1524del15858	p.S290C;T291_S319del
<i>PSEN1</i>	chr14:g.73673093G>A	c.869-1G>A	p.S290C;T291_S319del
<i>PSEN1</i>	chr14:g.73673093G>T	c.869-1G>T	p.S290C;T291_S319del
<i>PSEN2</i>	chr1:g.227073304A>T	c.422A>T	p.Asn141Ile

**Supplemental Table 3: Effect of Reference Region on PiB PET Findings**


<i>Reference Region:</i>	<b>Domain-Based Grouping</b>	<b>Codon-Based Grouping</b>
Cerebellar Gray	F(9,170.96) = 5.82, p = 3.32e-7	F(1,154.99) = 21.70, p = 2.24e-6
Brainstem	F(9,173.90) = 4.85, p = 3.13e-6	F(1,156.60) = 9.70, p = 0.0036
White Matter	F(9,173.35) = 5.14, p = 1.69e-5	F(1,154.96) = 11.55, p = 0.0016

*P-values shown are FDR corrected*


**Supplemental Table 4: Sensitivity Analyses Examining Variant Grouping x EYO Associations with Cortical PiB PET SUVR**

	Effect of Domain Grouping		Effect of Codon Grouping	
	F Value	p	F Value	p
Including All Families and Groupings	F(9, 170.96) = 5.17	p = 3.13e-06	F(1, 154.99) = 21.71	p = 2.24e-05
Excluding Families with Cooks D > 1 SD from mean	F(9, 149.24) = 5.98	p = 3.14e-06	F(1, 145.15) = 24.18	p = 1.22e-05
Excluding PSEN2 Carriers	F(8, 165.47) = 5.27	p = 2.24e-05	NA	NA
Excluding APP Carriers	F(8, 149.28) = 6.32	p = 3.13e-06	NA	NA
Excluding All APOE ε4 carriers	F(9, 107.80) = 4.81	p = 5.21e-05	F(1, 104.762) = 15.32	p = 3.23e-04
Excluding All APOE ε2 carriers	F(9, 139.53) = 3.18	p = 2.67e-03	F(1, 134.542) = 16.94	p = 1.51e-04
Covarying Weighted Polygenic AD Risk Scores (PRS)	F(9, 164.55) = 5.14	p = 1.70e-05	F(1, 153.69) = 21.13	p = 2.44e-05
Excluding PRS > 1 SD from mean	F(9, 139.61) = 5.68	p = 6.36e-06	F(1, 135.43) = 15.71	p = 2.58e-04


*P-values shown are FDR corrected*




**Supplemental Figure 1:** *Amyloid Measures Grouped by Global Clinical Dementia Rating: Cortical mean PiB PET binding (Panel A) and CSF A $\beta$ 42 (Panel B) in autosomal dominant Alzheimer's disease pathogenic variant carriers grouped by global Clinical Dementia Rating (CDR). Color indicates each individual pathogenic variant carrier's estimated years from symptom onset (EYO).*



**Supplemental Figure 2:** *Amyloid Trajectories Differ Across Domain-based Variant Groups:* Cortical mean PiB PET binding across EYO is compared between each domain-based group (colored lines in A-F) and all other pathogenic variant carriers (Black lines). Pathogenic variant non-carriers (Blue line) are shown for illustration purposes and non-carriers were not included in statistical comparisons. \* denotes FDR corrected  $p \leq 0.05$  for a significant group by EYO interaction comparing each domain-based group to all other pathogenic variant carriers.





**Supplemental Figure 3:** *Regional Variability in Amyloid Burden: Examples of Striatal Predominant Patterns.* Three examples across a range of estimated years to symptom onset (EYO) and impairment (Clinical Dementia Rating: CDR; Sum of Boxes: SOB) that show greater striatal compared to cortical amyloid burden as assessed by PiB PET. These images were chosen to demonstrate the heterogeneity present in  $\beta$ -amyloid measures across the course of autosomal dominant Alzheimer's disease. Transmembrane domain abbreviated as TM.





**Supplemental Figure 4:** CSF Aβ42/Aβ40 across variant groupings: Ratios of CSF Aβ42/40 were calculated for domain-based variant groupings (Panel A) and the PSEN1 codon 200 based grouping (Panel B). \* denotes FDR corrected  $p < 0.05$  for a significant variant group by EYO interaction.




**A.**

**Supplemental Figure 5:** *CSF Aβ42 Relative to Amyloid PET, Accounting for Variant Category:* Relationships between CSF Aβ42 and PET based measures of β-amyloid burden were assessed across all domain-based variant groupings (Panel A) and across individual variant groupings (Panels B-J). Only pathogenic variant carriers are shown.



**Supplemental Figure 6:** CSF A $\beta$ 42/ A $\beta$ 40 Ratio Relative to Amyloid PET, Accounting for Variant Category: Relationships between the CSF A $\beta$ 42/40 ratio and PET based measures of  $\beta$ -amyloid burden were assessed across all domain-based variant groupings (Panel A) and across individual variant groupings (Panels B-J). Only pathogenic variant carriers are shown.



**Supplemental Figure 7: Effects of Family Membership on Amyloid PET Results:** Influence metrics were calculated for each family in the sample in models examining associations between PiB PET and domain-based variant groupings. Colors denote each domain-based group. Dashed line indicates 1 standard deviation above the group mean value for the influence metric used (Cook's D).